The prediction was that if the enhanced rate of tumor growth observed with CMS4-IRF8lo cells was due at least in part to higher MMP3 levels, then attenuating MMP3 expression altogether should reduce this IRF8-dependent growth advantage. The gene discussed is IRF8; the disease is neoplasm.